BDB025 / Birdiebio - LARVOL DELTA

Overcoming PD-1 resistance with a first-in-class dual-mode agent that transforms 'cold' tumors to 'hot' (AACR 2026) - "We demonstrate a paradigm-shifting therapeutic strategy: a single molecule that pharmacologically induces a synthetic dMMR state by co-opting two synergistic mechanisms of action. Our lead candidate, BDB025, effectively breaks PD-1 resistance, paving the way to extend the curative potential of immunotherapy to the vast population of patients with pMMR cancers.Keywords: PD-1 resistance, colorectal cancer, MSI-H, DNA mismatch repair, MSH2, MSH6"

IO biomarker • Tumor mutational burden • Colorectal Cancer • Microsatellite Instability • Oncology • Solid Tumor • MSH2 • MSH6 • MSI • TMB